ClinicalTrials.gg
Active, not recruitingNCT05775094Updated Dec 19, 2025

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

A Phase 1 interventional study of Romosozumab in Osteoporosis and Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.

Planned enrollment
20th of 20
10 · median 80
Started
2023
with 2 others
Phase 1
3 of 20
none open now
Registered
13th of 20
by date
Lead sponsor
1 of 20
Memorial Sloan Kettering Cancer Center

Among the 20 studies testing romosozumab in Osteoporosis, this one is the 20th largest by planned enrollment, is one of 3 that started in 2023, is one of 3 in phase 1, and was the 13th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing romosozumab in Osteoporosis, or all of them as a file.
02

Study summary

The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in postmenopausal people with multiple myeloma (MM).

03

Conditions studied

  • Osteoporosis
  • Multiple Myeloma

Keywords

  • Romosozumab
  • 23-038
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented MM per International Myeloma Working Group diagnostic criteria (evidence of myeloma defining event attributed to underlying plasma cell disorder): i. Clonal plasma cells in the bone marrow ≥ 10% or presence of a proven plasmacytoma; and ii. Any one or more of the following myeloma defining events:
  • Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder:

    1. Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the or >2.75 mmol/L (>11 mg/dL)
    2. Renal insufficiency: \< 40 mL/min or serum creatinine 177µmol/L (>2 mg/dL)
    3. Anemia: > 2 g/dL below the lower limit of normal, or a hemoglobin value \<10 g/dL
    4. Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET/CT
  • Clonal bone marrow plasma cell percentage ≥ 60%; or
  • Involved: uninvolved serum free light chain (FLC) ratio ≥ 100 (involved FLC level be ≥ 10 mg/dL; or
  • >1 focal lesion on MRI studies (at least 5 mm in size)
  • Presence of lytic bone lesion(s) due to MM based on radiographic evidence with at least one (≥0.5 cm in its largest diameter by computerized tomography [CT])
  • female, defined as last menstrual cycle at least 12 months prior to study enrollment
  • Must have one of the following:

    • osteoporosis on dual X-ray absorptiometry (DXA) scan; or
    • fragility fracture of the spine or hip; or
    • morphometric spine fracture; or
    • osteopenia with elevated risk of fracture (calculated by the FRAX online calculator)
  • Within 12 months prior to study entry, ≤ 4 doses of prior intravenous (IV) bisphosphonate with the last dose ≥ 3 months prior to study entry.
  • Prior oral bisphosphonates are allowed if the last dose was ≥ 3 months prior to study entry.
  • Prior denosumab use is allowed for the following:

    • For patients who received ≤ 5 consecutive doses of denosumab with the last dose of denosumab received ≥ 3 months prior to study entry.
    • For patients who received ≥ 6 doses of denosumab, IV bisphosphonate should be given at least 1 month after the last dose of denosumab (if the last dose of denosumab was within the past 2 years). Patients are then eligible ≥ 3 months after IV bisphosphonate is received. If ≤ 2 years have elapsed since the last dose of denosumab, IV bisphosphonate is not required, and patients are eligible for the study.
  • Signed form(s). Individuals with impaired decision-making capacity may enroll if legally authorized representatives consent on behalf of individuals with impaired decision-making capacity.
  • Ability to comply with all study-related procedures in the investigator's judgment
  • 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  • Assigned male at birth
  • Received teriparatide or other PTH analog use within 12 months prior to study entry
  • Receiving concurrent antiresorptive therapy
  • History of cardiovascular event (myocardial infarction and/or stroke) within the past 12 months of study entry
  • History of non-healed dental or oral surgery
  • History of osteonecrosis of the jaw
  • 25 (OH) vitamin D levels \< 20 ng/mL. Vitamin D repletion will be permitted and subjects may be rescreened once 25 (OH) vitamin D level ≥ 20 ng/mL.
  • Current hyper- or hypocalcemia, defined as albumin-adjusted serum calcium outside the normal range per institutional standard (\<8.5 or >10.5 mg/dL).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Romosozumab

    Romosozumab will be given on-label for osteoporosis at 210 mg administered SC once monthly for 12 months in conjunction with antimyeloma therapy.

    Drug: Romosozumab

Interventions

  • Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).

06

What researchers measure

Primary outcomes

  1. Percent change in bone formation marker, P1NP

    Time frame: up to 2 years

Secondary outcomes

  1. Incidence and severity of adverse events

    evaluating adverse events using NCI CTCAE v5.0.

    Time frame: up to 2 years

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2027, 48 months after the start.

Of 30 phase 1 interventional studies under Osteoporosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
Mar 20, 2023
StartActual
Mar 7, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05775094
Responsible party
Sponsor
First posted
Mar 20, 2023
Start date
Mar 7, 2023
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Dec 19, 2025

Study contacts

Carlyn Tan, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion